Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACTS<br />
Martin Welschof<br />
Chief Executive Officer<br />
Loretta Greene<br />
Executive Assistant & Administrator<br />
ADDRESS<br />
OPSONA Therapeutics Ltd<br />
Second Floor Ashford House<br />
Tara Street<br />
Dublin 2<br />
Ireland<br />
TELEPHONE<br />
+353 1 677 0223<br />
FAX<br />
+ 353 1 677 8949<br />
EMAIL<br />
mwelschof@opsona.com<br />
lgreene@opsona.com<br />
YEAR FOUNDED<br />
2004<br />
Opsona Therapuetics<br />
www.opsona.com<br />
FINANCIAL SUMMARY<br />
Biotechnology Company<br />
0-20 Employees<br />
Private Company<br />
Latest Round of Funding – B Round<br />
Funding Total to date – $35M<br />
COMPANY PROFILE<br />
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to<br />
key targets of the innate immune system associated with a wide range of major human diseases, including<br />
autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer’s disease and<br />
atherosclerosis.<br />
The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of<br />
Ireland’s leading academic institution with a core focus on immunology research. Opsona’s lead product, a fully<br />
human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in<br />
a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers.<br />
The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to<br />
evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft<br />
Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.<br />
The Company is supported by an international venture consortium including Novartis Venture Fund, Roche<br />
Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and<br />
Enterprise Ireland.<br />
MANAGEMENT<br />
Bernd Seizinger, Executive Chairman<br />
Martin Welschof, CEO<br />
Mary Reilly, VP Pharmaceutical Development & Operations<br />
Luke O’Neill, Co-Founder, Director and CSO<br />
Conor Dalton, Finance Director<br />
Dr Robert M Miller, Consultant Chief Medical Officer<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language